Benlysta Rejected for Funding in Britain

Britain’s National Institute for Health and Care Excellence (NICE) rejected funding for Benlysta, the first new treatment for the condition in half a century, after reconsidering its earlier decision per an appeal by the manufacturer GlaxoSmithKline.  NICE recommends which drugs should be funded by Britain's state health service.